Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Nanobiotix S.A.NASDAQ: NBTX

Income Tax Expense · Q4 FY2025 · quarter ended Dec 2025

Income tax expense remains negative

Q4 FY2025 income tax expense was -€3K, compared with -€43K a year earlier. Over 3 fiscal years it compounded at -33.1% a year.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€3K— QoQ
Last fiscal yearDec 2025
€3K-97.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.0%——
1 year-97.0%——
3-year CAGR-33.1%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

EUR · from the income statement

Latest · FY2025
3K EUR
Year-over-year change
-97.0%
4-year CAGR
-12.0%

Income Tax Expense vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.0% is the lowest of 4, against a peer median of -33.6%.
  • Income tax expense amounts to 0.0% of revenue for NBTX, versus a peer median of 0.1%.
NBTX Competitors
Income Tax Expense for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$4.7M USD+177.1%+117.3%2.1%
KURAKura Oncology, Inc.LTM Mar 2026$79K USD-96.5%—0.1%
IMMXImmix Biopharma, Inc.LTM Mar 2026$27.9K USD-33.6%+54.3%—
NBTXNanobiotix S.A.FY2025€3K EUR-97.0%-33.1%0.0%
TYRATyra Biosciences, Inc.LTM Mar 2026$0 USD———
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD———
IBRXImmunityBio, Inc.LTM Sep 2026-$144K USD——0.1%
Peer median (excluding NBTX) —-33.6%+85.8%0.1%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.65M4.78M36.21M(7.19M)29.64M
Cost of Revenue00000
Gross Profit2.65M4.78M36.21M(7.19M)29.64M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development30.38M32.64M38.4M40.54M23.12M
Selling, General & Admin19.43M17.86M22.05M20.53M20.22M
Operating Expenses55.23M51.48M62.99M61.2M40.46M
Depreciation & Amortization1.56M1.5M551K592K1.5M
EBITDA(45.61M)(44.22M)(23.69M)(67.67M)(12.07M)
EBITDA Margin-1722.9%-925.8%-65.4%941.1%-40.7%
Operating Income(52.58M)(46.7M)(26.78M)(68.39M)(10.82M)
Operating Margin-1986.4%-977.8%-74.0%951.2%-36.5%
Interest Income0256K1.22M2.63M985K
Interest Expense699.49K5.84M7.98M8.09M10.4M
Other Income / Expenses5.58M(10.33M)(12.8M)361K(13.14M)
Income Before Tax(47M)(57.03M)(39.58M)(68.03M)(23.96M)
Pre-Tax Margin-1775.5%-1194.1%-109.3%946.2%-80.8%
Income Tax Expense5K10K120K101K3K
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Net Margin-1775.7%-1194.3%-109.6%947.6%-80.8%
EPS (Basic)(1.35)(1.64)(1.08)(1.44)(0.50)
EPS (Diluted)(1.35)(1.64)(1.08)(1.44)(0.50)
Weighted Avg Shares34.73M34.85M36.76M47.27M47.82M
Weighted Avg Shares (Diluted)34.73M34.85M36.93M47.27M47.82M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.